Tauklarify (florquinitau F 18 injection) is a brain PET tracer that highlights tau tangles inside neurons in adults with thinking problems. Amyloid PET highlights plaques between neurons as an earlier signal, while tau PET tracks more closely with memory loss and disease stage.
Lantheus announced the approval on Aug. 14, 2026 for cognitively impaired adults being evaluated for Alzheimer's the FDA approval notice. Younger-onset means symptoms before age 65, a situation the Alzheimer's Association describes on its younger-onset help page.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from Lantheus — Use this primary source to verify the official announcement.
- Read the official guidance from Curealz — Use this primary source to verify the official guidance.
Table of Contents
- What does each scan show?
- What did the 2026 approval add?
- Why does tau detail matter before age 65?
- What are the limits and next steps?
What does each scan show?
Amyloid PET detects plaques that build up between brain cells. Tau PET visualizes tangles that form inside brain cells. The Cure Alzheimer's Fund explains that tangles track more closely with cognitive loss and staging its tau imaging explainer.
Think of amyloid as an early warning light. Think of tau as a gauge of where damage stands. A person can have amyloid buildup with mild symptoms. Heavy neocortical tau more often matches clear impairment.
What did the 2026 approval add?
Tauklarify is an F-18-labeled tau tracer for PET imaging. It gives clinics another tau option alongside amyloid PET and clinical testing. Doctors can order it when tau information would clarify diagnosis or stage.
Approval rested on scans read by blinded readers. Agreement was stronger for negative scans than for positive scans. Performance can be lower earlier in the disease course.
Why does tau detail matter before age 65?
Work, parenting, and finances often depend on a precise diagnosis in midlife. An amyloid result alone may leave the stage unclear. A tau pattern helps the clinician link symptoms to disease extent.
Families also face decisions about treatment access, safety at work, and driving. Tau staging gives clearer context for those talks. It does not replace memory testing, exams, or lab work.
What are the limits and next steps?
Lantheus states that safety and effectiveness are not established for non-Alzheimer's tauopathies the FDA approval notice. A negative scan does not exclude tau pathology.
A positive scan alone does not confirm it. Ask the memory clinic these questions before scheduling: Bring a symptom timeline, medication list, and a partner who sees daily function.
- Will amyloid testing come first, or is tau needed now?
- How will the result change diagnosis, care, or trial eligibility?
- What is the radiation dose, cost, and insurance coverage?
- Where will a reader experienced in tau PET interpret the scan?
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
